The first includes the administration of two chemokines that potentiate the activity of effector CD4+ and CD8+ T cells and the other that selectively deplete CCR8+ regulatory T cells that are likely to be the dominant regulatory T cells within the TME of several human tumors, among them breast cancer. Here, CD8A is linked to breast cancer.